recombinant proteins


Summary: Proteins prepared by recombinant DNA technology.

Top Publications

  1. ncbi Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
  2. ncbi Protein production by auto-induction in high density shaking cultures
    F William Studier
    Biology Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    Protein Expr Purif 41:207-34. 2005
  3. pmc Boceprevir for untreated chronic HCV genotype 1 infection
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    N Engl J Med 364:1195-206. 2011
  4. ncbi Telaprevir for previously untreated chronic hepatitis C virus infection
    Ira M Jacobson
    Weill Cornell Medical College and Center for the Study of Hepatitis C, New York, NY 10021, USA
    N Engl J Med 364:2405-16. 2011
  5. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  6. ncbi Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein
    Nathan C Shaner
    Nat Biotechnol 22:1567-72. 2004
  7. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
  8. pmc Boceprevir for previously treated chronic HCV genotype 1 infection
    Bruce R Bacon
    Saint Louis University School of Medicine, St Louis, Mo 63110 0250, USA
    N Engl J Med 364:1207-17. 2011
  9. ncbi Telaprevir for retreatment of HCV infection
    Stefan Zeuzem
    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
    N Engl J Med 364:2417-28. 2011
  10. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001

Detail Information

Publications369 found, 100 shown here

  1. ncbi Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
  2. ncbi Protein production by auto-induction in high density shaking cultures
    F William Studier
    Biology Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    Protein Expr Purif 41:207-34. 2005
    ..Selenomethionine labeling was equally efficient in the commonly used methionine auxotroph B834(DE3) (found to be metE) or the prototroph BL21(DE3)...
  3. pmc Boceprevir for untreated chronic HCV genotype 1 infection
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    N Engl J Med 364:1195-206. 2011
    ..The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies...
  4. ncbi Telaprevir for previously untreated chronic hepatitis C virus infection
    Ira M Jacobson
    Weill Cornell Medical College and Center for the Study of Hepatitis C, New York, NY 10021, USA
    N Engl J Med 364:2405-16. 2011
  5. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  6. ncbi Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein
    Nathan C Shaner
    Nat Biotechnol 22:1567-72. 2004
    ..Three monomers with distinguishable hues from yellow-orange to red-orange have higher quantum efficiencies...
  7. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  8. pmc Boceprevir for previously treated chronic HCV genotype 1 infection
    Bruce R Bacon
    Saint Louis University School of Medicine, St Louis, Mo 63110 0250, USA
    N Engl J Med 364:1207-17. 2011
    ..Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an additional treatment...
  9. ncbi Telaprevir for retreatment of HCV infection
    Stefan Zeuzem
    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
    N Engl J Med 364:2417-28. 2011
    ..Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin...
  10. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    ..In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin...
  11. pmc Response-guided telaprevir combination treatment for hepatitis C virus infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    N Engl J Med 365:1014-24. 2011
    ..We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations...
  12. ncbi Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008
    R Phillip Dellinger
    Cooper University Hospital, Camden, NJ, USA
    Crit Care Med 36:296-327. 2008
    ..To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock," published in 2004...
  13. ncbi Generation of induced pluripotent stem cells using recombinant proteins
    Hongyan Zhou
    Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA
    Cell Stem Cell 4:381-4. 2009
  14. ncbi Binding of hepatitis C virus to CD81
    P Pileri
    IRIS, Chiron, Siena 53100, Italy
    Science 282:938-41. 1998
    ..Binding of E2 was mapped to the major extracellular loop of CD81. Recombinant molecules containing this loop bound HCV and antibodies that neutralize HCV infection in vivo inhibited virus binding to CD81 in vitro...
  15. ncbi Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
    ..Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment...
  16. ncbi Identification of a major co-receptor for primary isolates of HIV-1
    H Deng
    Skirball Institute for Biomolecular Medicine, New York University Medical Center, 10016, USA
    Nature 381:661-6. 1996
    ..The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR-5, a receptor for the beta-chemokines RANTES, MIP-1alpha and MIP-1beta...
  17. pmc High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells
    Yves Durocher
    Animal Cell Technology and Downstream Processing Group, Biotechnology Research Institute, National Research Council Canada, 6100 Royalmount Avenue, Montreal, Quebec H4P 2R2, Canada
    Nucleic Acids Res 30:E9. 2002
    ..Using the pTT vector, >20 mg/l of purified His-tagged SEAP was recovered from a 3.5 l bioreactor. Intracellular proteins were also produced at levels as high as 50 mg/l, representing up to 20% of total cell proteins...
  18. ncbi Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
    Andri Rauch
    University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    Gastroenterology 138:1338-45, 1345.e1-7. 2010
    ..We performed a genome-wide association study to screen for host genetic determinants of HCV persistence and response to therapy...
  19. ncbi Green fluorescent protein as a marker for gene expression
    M Chalfie
    Department of Biological Sciences, Columbia University, New York, NY 10027
    Science 263:802-5. 1994
    ..Because exogenous substrates and cofactors are not required for this fluorescence, GFP expression can be used to monitor gene expression and protein localization in living organisms...
  20. ncbi Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    Tilman B Drueke
    Inserm Unité 507 and Assistance Publique Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris, France
    N Engl J Med 355:2071-84. 2006
    ..Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established...
  21. ncbi Preliminary study of two antiviral agents for hepatitis C genotype 1
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    N Engl J Med 366:216-24. 2012
    ..Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen...
  22. ncbi Correction of anemia with epoetin alfa in chronic kidney disease
    Ajay K Singh
    Renal Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 355:2085-98. 2006
    ..Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin correction is not defined...
  23. ncbi Functional interaction of beta-catenin with the transcription factor LEF-1
    J Behrens
    Max Delbruck Centre for Molecular Medicine, Berlin, Germany
    Nature 382:638-42. 1996
    ..Thus beta-catenin regulates gene expression by direct interaction with transcription factors such as LEF-1, providing a molecular mechanism for the transmission of signals, from cell-adhesion components or wnt protein to the nucleus...
  24. ncbi HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
    Y Feng
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases NIAID, NIH, Bethesda, MD 20892, USA
    Science 272:872-7. 1996
    ..Fusin messenger RNA levels correlated with HIV-1 permissiveness in diverse human cell types. Fusin acted preferentially for T cell line-tropic isolates, in comparison to its activity with macrophagetropic HIV-1 isolates...
  25. pmc The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus
    Elisa Scarselli
    Istituto di Ricerche di Biologia Molecolare P Angeletti IRBM, Via Pontina Km 30 600, 00040 Pomezia Rome, Italy
    EMBO J 21:5017-25. 2002
    ..Finally, E2 recognition by SR-BI was competed out in an isolate-specific manner both on the hepatoma cell line and on the human SR-BI-transfected cell line by an anti-HVR1 monoclonal antibody...
  26. ncbi Effects of the obese gene product on body weight regulation in ob/ob mice
    M A Pelleymounter
    Department of Neurobiology, Amgen, Inc, Thousand Oaks, CA 91320, USA
    Science 269:540-3. 1995
    ..These data suggest that the OB protein regulates body weight and fat deposition through effects on metabolism and appetite...
  27. ncbi Genome sequence of the recombinant protein production host Pichia pastoris
    Kristof De Schutter
    Unit for Molecular Glycobiology, Department for Molecular Biomedical Research, VIB, Ghent Zwijnaarde, Belgium
    Nat Biotechnol 27:561-6. 2009
    ..pastoris. To facilitate progress in these areas, we present the 9.43 Mbp genomic sequence of the GS115 strain of P. pastoris. We also provide manually curated annotation for its 5,313 protein-coding genes...
  28. ncbi A time- and cost-efficient system for high-level protein production in mammalian cells
    A Radu Aricescu
    Cancer Research UK Receptor Structure Research Group, Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, England
    Acta Crystallogr D Biol Crystallogr 62:1243-50. 2006
    ..The system is suitable for use in conventional laboratories or can be implemented in a medium- or high-throughput pipeline...
  29. ncbi An improved cyan fluorescent protein variant useful for FRET
    Mark A Rizzo
    Nat Biotechnol 22:445-9. 2004
    ..Cerulean is 2.5-fold brighter than ECFP and replacement of ECFP with Cerulean substantially improves the signal-to-noise ratio of a FRET-based sensor for glucokinase activation...
  30. ncbi Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:580-93. 2009
    ..Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared...
  31. pmc High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes
    U Andersson
    Department of Medicine, Rheumatology Unit, Karolinska Hospital, 17176 Stockholm, Sweden
    J Exp Med 192:565-70. 2000
    ..Together, these results indicate that, like other cytokine mediators of endotoxin lethality (e.g., TNF and IL-1), extracellular HMG-1 is a regulator of monocyte proinflammatory cytokine synthesis...
  32. ncbi Heterologous protein production using the Pichia pastoris expression system
    Sue Macauley-Patrick
    Strathclyde Fermentation Centre, Department of Bioscience, University of Strathclyde, 204 George Street, Glasgow G1 1XW, UK
    Yeast 22:249-70. 2005
    ..The problems associated with post-translational modifications performed on recombinant proteins by P...
  33. ncbi 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    M S Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, 1, route du Muids, 1272 Genolier, Switzerland
    Eur J Cancer 47:8-32. 2011
    ..Evidence from multiple low level studies derived from audit data and clinical practice suggests that some patients receive suboptimal daily G-CSFs; the use of pegfilgrastim may avoid this problem...
  34. ncbi Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
    ..Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment...
  35. ncbi Recombinant protein expression in Escherichia coli
    F Baneyx
    Department of Chemical Engineering University of Washington Box 351750, Seattle, WA 98195, USA
    Curr Opin Biotechnol 10:411-21. 1999
    ..coli, together with serendipitous discoveries and the availability of improved genetic tools are making this bacterium more valuable than ever for the expression of complex eukaryotic proteins...
  36. pmc Identification and characterization of a family of mammalian methyl-CpG binding proteins
    B Hendrich
    Institute of Cell and Molecular Biology, University of Edinburgh, Edinburgh EH9 3JR, Scotland
    Mol Cell Biol 18:6538-47. 1998
    ..The data demonstrate that MBD2 and MBD4 bind specifically to methyl-CpG in vitro and in vivo and are therefore likely to be mediators of the biological consequences of the methylation signal...
  37. pmc Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice
    Jing Xu
    Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA
    Diabetes 58:250-9. 2009
    ..The aims of the current study are to evaluate the role of FGF21 in energy metabolism and to provide mechanistic insights into its glucose and lipid-lowering effects in a high-fat diet-induced obesity (DIO) model...
  38. ncbi Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Hiromitsu Kumada
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 56:78-84. 2012
    ..To evaluate the efficacy and safety of telaprevir in combination with peginterferon-α2b (PEG-IFN) and ribavirin (RBV) in patients with chronic hepatitis C...
  39. ncbi Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C
    Masao Honda
    Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Gastroenterology 139:499-509. 2010
    ..Multiple viral and host factors are related to the treatment response to pegylated-interferon and ribavirin combination therapy; however, the clinical relevance and relationship of these factors have not yet been fully evaluated...
  40. pmc The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody
    Alexander D Douglas
    Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
    Nat Commun 2:601. 2011
    ..falciparum is a degenerate process involving a series of parallel redundant pathways...
  41. ncbi Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity
    Utpal B Pajvani
    Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Biol Chem 278:9073-85. 2003
    ..Combined, these results shed new light on the regulation of this complex protein and suggest a new model for in vivo activation of the protein, implicating a serum reductase activity...
  42. ncbi Nuclear export of microRNA precursors
    Elsebet Lund
    Department of Biomolecular Chemistry, University of Wisconsin Medical School, Madison, WI 53706, USA
    Science 303:95-8. 2004
    ..Thus, Exp5 is key to miRNA biogenesis and may help coordinate nuclear and cytoplasmic processing steps...
  43. ncbi Crystal structure of a mammalian voltage-dependent Shaker family K+ channel
    Stephen B Long
    Howard Hughes Medical Institute, Laboratory of Molecular Neurobiology and Biophysics, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 309:897-903. 2005
    ..Electrostatic properties of the side portals and positions of the T1 domain and beta subunit are consistent with electrophysiological studies of inactivation gating and with the possibility of K+ channel regulation by the beta subunit...
  44. ncbi Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3
    H Zou
    Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 75235, USA
    Cell 90:405-13. 1997
    ..The COOH-terminal region of Apaf-1 comprises multiple WD repeats, which are proposed to mediate protein-protein interactions. Cytochrome c binds to Apaf-1, an event that may trigger the activation of caspase-3, leading to apoptosis...
  45. pmc Interferon signaling and treatment outcome in chronic hepatitis C
    Magdalena Sarasin-Filipowicz
    Department of Biomedicine, University of Basel, CH 4031 Basel, Switzerland
    Proc Natl Acad Sci U S A 105:7034-9. 2008
  46. ncbi Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production
    Rachel Daly
    ARC Special Research Centre for Green Chemistry, Monash University, Building 23, Wellington Road, Clayton, Victoria 3800, Australia
    J Mol Recognit 18:119-38. 2005
    The use of the methylotrophic yeast, Pichia pastoris, as a cellular host for the expression of recombinant proteins has become increasing popular in recent times. P...
  47. ncbi Advanced genetic strategies for recombinant protein expression in Escherichia coli
    Hans Peter Sørensen
    Laboratory of BioDesign, Department of Molecular Biology, Aarhus University, Gustav Wieds Vej 10 C, DK 8000 Aarhus C, Denmark
    J Biotechnol 115:113-28. 2005
    ..The macromolecular background for a variety of obstacles and genetic state-of-the-art solutions are presented...
  48. ncbi Cell-free translation reconstituted with purified components
    Y Shimizu
    Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Bldg FSB401, Kasiwanoha, Kashiwa, Chiba Prefecture 277-8562, Japan
    Nat Biotechnol 19:751-5. 2001
    ..Moreover, omission of a release factor allowed efficient incorporation of an unnatural amino acid using suppressor transfer RNA (tRNA)...
  49. ncbi Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
    Gastroenterology 132:1767-77. 2007
    ..4A protease inhibitor, has shown strong antiviral activity in phase 1 clinical studies. Because of high levels of HCV replication and the low fidelity of HCV polymerase, selection of resistant isolates during therapy may occur...
  50. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
    ..We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCV patients...
  51. ncbi Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Thoracic Head and Neck Medicine Clinic, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 28:2839-46. 2010
    ..To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer...
  52. ncbi Overproduction of recombinant proteins in plants
    Erin Egelkrout
    Applied Biotechnology Institute, Cal Poly Technology Park, Building 83, San Luis Obispo, CA 93407, USA
    Plant Sci 184:83-101. 2012
    ..Plants as alternative hosts for the production of recombinant proteins are being actively pursued, taking advantage of their unique characteristics...
  53. ncbi TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Devalingam Mahalingam
    Department of Biochemistry and National Centre for Biomedical Engineering Science, National University of Ireland, Galway, University Road, Galway, Ireland
    Cancer Treat Rev 35:280-8. 2009
  54. pmc Genome-scale metabolic reconstruction and in silico analysis of methylotrophic yeast Pichia pastoris for strain improvement
    Bevan Ks Chung
    NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, 28 Medical Drive, 05 01, 117456, Singapore
    Microb Cell Fact 9:50. 2010
    ..pastoris can be employed together with high throughput experimental data analysis, for better understanding of the methylotrophic yeast's metabolism...
  55. pmc High-throughput production of human proteins for crystallization: the SGC experience
    Pavel Savitsky
    Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford, UK
    J Struct Biol 172:3-13. 2010
    ..These can be used to formulate guidelines for initial approaches to expression of new eukaryotic proteins...
  56. ncbi Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C
    Michael T Dill
    Department of Biomedicine, Hepatology Laboratory, University of Basel, Basel, Switzerland
    Gastroenterology 140:1021-31. 2011
    ..We investigated whether IL28B genotype determines the constitutive expression of ISGs in the liver and compared the abilities of ISG levels and IL28B genotype to predict treatment outcome...
  57. pmc T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines
    F Fossiez
    Schering Plough, Laboratory for Immunological Research, Dardilly, France
    J Exp Med 183:2593-603. 1996
    ..These observations suggest that hIL-17 may constitute (a) an early initiator of the T cell-dependent inflammmatory reaction; and (b) an element of the cytokine network that bridges the immune system to hematopoiesis...
  58. ncbi Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
    Ming Lung Yu
    Department of Internal Medicine, Kaohsiung Municipal Ta Tung Hospital, Kaohsiung, Taiwan
    Hepatology 53:7-13. 2011
    ..99-1.00, P = 0.04). Nevertheless, the achievement of RVR was the single predictor of SVR with an OR of 19.37 (95% CI = 8.89-42.23, P < 0.001), whereas the rs8099917 genotypes played no role in achieving SVR with or without RVR...
  59. ncbi IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...
  60. ncbi Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
    Manuel Romero-Gomez
    Hepatology Unit, Hospital Universitario de Valme, Sevilla, Spain
    Gastroenterology 128:636-41. 2005
    ..We evaluated the effect of insulin resistance and viral factors on sustained virological response in patients with chronic hepatitis C treated with peginterferon plus ribavirin...
  61. ncbi Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
    ..Due to the lack of head-to-head studies, the 2 PegIFNs have not been directly compared. The endpoints of our study were safety and antiviral efficacy of the 2 regimens...
  62. ncbi Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution
    R B Sutton
    The Howard Hughes Medical Institute, Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, USA
    Nature 395:347-53. 1998
    ..These characteristics may be important for membrane fusion and for the binding of regulatory factors affecting neurotransmission...
  63. pmc Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog
    S R Hubbard
    Department of Pharmacology and Skirball Institute of Biomolecular Medicine, 540 First Avenue, New York University Medical Center, New York, NY 10016, USA
    EMBO J 16:5572-81. 1997
    ..The structure thus reveals the molecular basis for insulin receptor activation via autophosphorylation, and provides insights into tyrosine kinase substrate specificity and the mechanism of phosphotransfer...
  64. pmc The Anopheles gambiae odorant binding protein 1 (AgamOBP1) mediates indole recognition in the antennae of female mosquitoes
    Harald Biessmann
    Developmental Biology Center, Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California, United States of America
    PLoS ONE 5:e9471. 2010
    ..gambiae OBP-ligand pairing combination, demonstrates the significance of OBPs in odor recognition, and can be expanded to the identification of other ligands for OBPs of Anopheles and other medically important insects...
  65. ncbi Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells
    C K Leonard
    Department of Medicinal Chemistry, Genentech, Inc, South San Francisco, California 94080
    J Biol Chem 265:10373-82. 1990
  66. ncbi CHO cells in biotechnology for production of recombinant proteins: current state and further potential
    Jee Yon Kim
    Department of Biological Sciences, Graduate School of Nanoscience and Technology WCU, KAIST, 373 1 Kusong Dong, Yuseong Gu, Daejeon 305 701, Korea
    Appl Microbiol Biotechnol 93:917-30. 2012
  67. ncbi Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
  68. pmc Bax directly induces release of cytochrome c from isolated mitochondria
    J M Jurgensmeier
    Program on Apoptosis and Cell Death Research, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 95:4997-5002. 1998
  69. ncbi Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
    Avi Ashkenazi
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    J Clin Oncol 26:3621-30. 2008
    ..Clinical studies are ongoing to assess the safety and efficacy of this novel agent in combination with established anticancer therapies...
  70. ncbi Recombinant protein production in a variety of Nicotiana hosts: a comparative analysis
    Andrew J Conley
    Department of Biology, University of Western Ontario, London, ON, Canada
    Plant Biotechnol J 9:434-44. 2011
    ..biopharmaceuticals and industrial enzymes, tobacco has the most established history for the production of recombinant proteins. To further improve the heterologous protein yield of tobacco platforms, transient and stable expression of ..
  71. pmc Pre-expression of a sulfhydryl oxidase significantly increases the yields of eukaryotic disulfide bond containing proteins expressed in the cytoplasm of E.coli
    Van Dat Nguyen
    Department of Biochemistry, Linnanmaa campus, University of Oulu, 90570 Oulu, Finland
    Microb Cell Fact 10:1. 2011
    ..We have recently shown that it is possible to produce large amounts of prokaryotic disulfide bond containing proteins in the cytoplasm of wild-type bacteria such as E. coli by the introduction of catalysts for both of these processes...
  72. ncbi Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
    ..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
  73. ncbi Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
    ..We tested the efficacy of boceprevir, an NS3 hepatitis C virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin...
  74. ncbi Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia
    Jack S Richards
    Department of Medical Biology, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia
    Clin Infect Dis 51:e50-60. 2010
    ..Erythrocyte-binding antigens (EBAs) are important erythrocyte invasion ligands used by merozoites and may be targets of protective immunity, but there are limited data examining their potential importance...
  75. ncbi Histone H4-K16 acetylation controls chromatin structure and protein interactions
    Michael Shogren-Knaak
    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Science 311:844-7. 2006
  76. ncbi The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
    Alexei Kharitonenkov
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Endocrinology 148:774-81. 2007
    ..These data support the development of FGF-21 for the treatment of diabetes and other metabolic diseases...
  77. ncbi Engineering of protein secretion in yeast: strategies and impact on protein production
    Alimjan Idiris
    R and D Group, ASPEX Division, Research Center, Asahi Glass Co, Ltd, 1150 Hazawa cho, Kanagawa ku, Yokohama, 221 8755, Japan
    Appl Microbiol Biotechnol 86:403-17. 2010
    ..This mini-review focuses on recent strategies and their advantages for systematic engineering of yeast strains for effective protein secretion...
  78. ncbi HEK293 cell line: a vehicle for the expression of recombinant proteins
    Philip Thomas
    Department of Pharmacology, University College London, Gower Street, London, WC1E 6BT, UK
    J Pharmacol Toxicol Methods 51:187-200. 2005
    The HEK cell line has been extensively used as an expression tool for recombinant proteins since it was generated over 25 years ago...
  79. ncbi A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
    M D Green
    Royal Melbourne Hospital, Melbourne, Australia
    Ann Oncol 14:29-35. 2003
    ..We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with daily administration of filgrastim, in the provision of neutrophil support...
  80. ncbi Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection
    Antonio Ascione
    Department of Gastroenterology, Liver Unit, Cardarelli Hospital, Napoli, Italy
    Gastroenterology 138:116-22. 2010
    ..This study compared the efficacy and safety of peginterferon alfa-2a and peginterferon alfa-2b, each in combination with ribavirin...
  81. pmc Functional amyloid formation within mammalian tissue
    Douglas M Fowler
    Department of Chemistry, The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, California, USA
    PLoS Biol 4:e6. 2006
  82. ncbi A companion protease inhibitor for the protection of cytosol-targeted recombinant proteins in plants
    Charles Goulet
    CRH INAF, Pavillon des Services INAF, Universite Laval, Quebec, QC, Canada
    Plant Biotechnol J 8:142-54. 2010
    ..potential of tomato cathepsin D inhibitor (SlCDI) as an in-built stabilizing agent for the protection of recombinant proteins in transgenic plant leaf crude extracts (Plant Biotechnol J.4, 359-368)...
  83. pmc Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870
    Vega Masignani
    IRIS, Chiron Srl, Via Fiorentina 1, 53100 Siena, Italy
    J Exp Med 197:789-99. 2003
    ..The novel antigen is a top candidate for the development of a new vaccine against meningococcus...
  84. ncbi Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria
    Jerry M Wells
    Host Microbe Interactomics, University of Wageningen, Animal Sciences Department, P O Box 338, 6700 AH, Wageningen, The Netherlands
    Nat Rev Microbiol 6:349-62. 2008
  85. ncbi Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response
    M Brines
    Warren Pharmaceuticals, Ossining, NY 10562, USA
    J Intern Med 264:405-32. 2008
  86. ncbi 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis
    Igor Mierau
    NIZO Food Research, P O Box 20, 6710, Ede, The Netherlands
    Appl Microbiol Biotechnol 68:705-17. 2005
    ..Finally, an overview is given of growth and induction conditions for lab-scale and industrial-scale applications...
  87. ncbi Cloning of a new cytokine that induces IFN-gamma production by T cells
    H Okamura
    Department of Bacteriology, Hyogo College of Medicine, Nishinomiya, Japan
    Nature 378:88-91. 1995
    ..IGIF may be involved in the development of Th1 cells and also in mechanisms of tissue injury in inflammatory reactions...
  88. ncbi Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
    A Furlan
    Cerebrovascular Center, Department of Neurology, Cleveland Clinic Foundation, Ohio 44195, USA
    JAMA 282:2003-11. 1999
    ..Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed...
  89. ncbi Structure and function of fatty acid amide hydrolase
    Michele K McKinney
    Departments of Cell Biology and Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Annu Rev Biochem 74:411-32. 2005
    ..These studies, as well as their biological and therapeutic implications, are the subject of this review...
  90. ncbi Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities
    Christopher M Jenkins
    Division of Bioorganic Chemistry and Molecular Pharmacology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 279:48968-75. 2004
  91. pmc Vaccine potential of the Neisseria meningitidis 2086 lipoprotein
    Leah D Fletcher
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    Infect Immun 72:2088-100. 2004
    ..The rLP2086 family of antigens are candidates worthy of further vaccine development...
  92. ncbi The production of recombinant pharmaceutical proteins in plants
    Julian K C Ma
    Department of Infectious Diseases, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
    Nat Rev Genet 4:794-805. 2003
    ..This could one day become reality as we learn to harness the power of plants for the production of recombinant proteins on an agricultural scale...
  93. pmc Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:642-58. 2003
    ..These reengineered gp120s are prospective immunogens that may prove capable of eliciting broadly neutralizing antibodies...
  94. pmc Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response
    Sebastián Bernales
    Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California, United States of America
    PLoS Biol 4:e423. 2006
    ..Selective ER sequestration may help cells to maintain a new steady-state level of ER abundance even in the face of continuously accumulating unfolded proteins...
  95. ncbi Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
    ..Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities...
  96. pmc Lytic activity of the virion-associated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88
    Lorena Rodriguez
    Instituto de Productos Lacteos de Asturias IPLA CSIC, Apdo, Asturias, Spain
    BMC Microbiol 11:138. 2011
    ..In this context, bacteriophage lytic enzymes such as endolysins and structural peptidoglycan (PG) hydrolases have received considerable attention as possible antimicrobials against gram-positive bacteria...
  97. ncbi Hepatitis C pharmacogenetics: state of the art in 2010
    Nezam H Afdhal
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 53:336-45. 2011
  98. ncbi Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease
    Ari Zimran
    Gaucher Clinic, Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel
    Blood 118:5767-73. 2011
    ..4, -32.8) in the 60-unit dose group (both P < .0001); and in all secondary efficacy end point measures, except platelet counts at the lower dose. These results support safety and efficacy of taliglucerase alfa for Gaucher disease...
  99. pmc Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients
    Tatsuo Miyamura
    Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
    PLoS ONE 6:e28617. 2011
  100. pmc Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA
    Anand Srivastava
    Institut Pasteur, Unité de Biologie des Interactions Hôte Parasite, Centre National de la Recherche Scientifique Unité de Recherche Associée 2581, 25 rue du Docteur Roux, F 75724 Paris Cedex 15, France
    Proc Natl Acad Sci U S A 107:4884-9. 2010
    ..These results have important consequences for the development of an effective vaccine and therapeutic inhibitors...
  101. ncbi Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha
    M L Moss
    Department of Molecular Biochemistry, Glaxo Wellcome Research and Development Inc, Research Triangle Park, North Carolina 27709, USA
    Nature 385:733-6. 1997
    ..The rTACE provides a readily available source of enzyme to help in the search for new anti-inflammatory agents that target the final processing stage of TNF-alpha production...

Research Grants78

    Adrian R Krainer; Fiscal Year: 2010
    ..achieved through a combination of biochemical approaches using cell-free systems, purified components, and recombinant proteins together with molecular and reverse-genetic approaches in cell culture, bioinformatics analysis of the ..
  2. Development of Vaccines against Clostridium difficile Infection
    SAUL R TZIPORI; Fiscal Year: 2013
    ..In this project, we will first evaluate the ability of these atoxic recombinant proteins to induce protective antibody responses following parenteral immunization followed by challenge with wild ..
    Buddy Ullman; Fiscal Year: 2003
    ..ii) Recombinant proteins. E. coli that overexpresses T...
  4. Identification of vaccine antigens based on expression in blood
    PETER TRIP BEERNINK; Fiscal Year: 2011
    ..In Aim 3 we will express recombinant proteins encoded by NmB genes that are up- regulated during infection and, based on genomic data, are predicted to ..
  5. Multiplex Serodiagnostic Protein Microarray
    PHILIP LOUIS FELGNER; Fiscal Year: 2012
    ..from this project include plasmids, customized protein microarrays in a modular multiplex format, purified recombinant proteins and lateral flow (dipstick)/immunostrips devices, and will be accessible from the PSWRCE Protein Microarray ..
    HYUNG D RYOO; Fiscal Year: 2010
    ..Tools to manipulate cells'secretory capacity may be used to enhance production of recombinant proteins in cultured cells or in gene therapy or cell therapy in vivo.
  7. Eukaryotic-type STK/STP-mediated modulation of enterococcal pathogenesis
    Vijay Pancholi; Fiscal Year: 2010
    ..To test this hypothesis, the contranscribing efstk and efstp genes will be cloned and corresponding recombinant proteins will be made to study their biochemical properties...
  8. Kynurenic Acid Synthesis in Mouse Brain
    Jianyong Li; Fiscal Year: 2010
    ..kynurenine and other substrates through the expression and extensive biochemical characterization of their recombinant proteins, (2) to determine the identity, relative amount and cellular localization of brain KATs through antigen- ..
  9. Transferrin Conjugates for Oral Protein Drug Delivery
    Wei Chiang Shen; Fiscal Year: 2013
    ..The objective of this application is to develop recombinant proteins by fusing protein drugs with an iron-carrying protein, transferrin, to promote oral absorption...
  10. Oral immune modulatory therapy using antigens bioencapsulated in plant cells
    Roland W Herzog; Fiscal Year: 2013
    ..applicant): Current treatment for many inherited protein deficiencies is based on intravenous infusion of recombinant proteins. The infused protein is expensive and is often encountered by antibody responses that neutralize therapy, ..
  11. Role of Mitochondrial Aldehyde Dehydrogenases in Ethanol Metabolism and Toxicity
    Vasilis Vasiliou; Fiscal Year: 2010
    ..This will be accomplished by studying the formation of heterotetramers using recombinant proteins and cell lines expressing these proteins.
  12. Cytoglobin: A stress-responsive hemoprotein modulating cardiomyocyte survival
    Pradeep P A Mammen; Fiscal Year: 2013
    ..Using recombinant proteins we show a direct protein-protein interaction between the two proteins...
  13. DNA Pro-Drug Technology in Localized Wound Healing and Tissue Regeneration
    Arthur A Decarlo; Fiscal Year: 2011
    ..Further, the combination of these recombinant proteins for more sophisticated approaches is complicated by the need for separate biologics...
  14. Role of the complement system in renal disease
    Richard J Quigg; Fiscal Year: 2011
    ..Through the use of genetically manipulated mice and recombinant proteins, and the techniques of bone marrow and kidney transplantation to determine effects of these proteins in ..
    Larry G Arlian; Fiscal Year: 2013 testing selected scabies mite proteins (both those isolated from mite extracts and expressed as recombinant proteins) for their ability to modulate the innate immune response of cultured skin cells and/or to be recognized by ..
  16. Development of a Recombinant Subunit Vaccine for CCHF
    David E Clements; Fiscal Year: 2013
    ..Based on immunogenicity studies, selected combinations of recombinant proteins and adjuvant will be evaluated in protective efficacy studies utilizing a recently developed mouse ..
  17. Bioactive lipids in food and pharmaceutical products
    Eric J Haas-Stapleton; Fiscal Year: 2013
    ..because this fungus is used to manufacture a wide range of products including alcoholic beverages and recombinant proteins for therapeutics and vaccines...
  18. Astrovirus structure and replication
    Yizhi Jane Tao; Fiscal Year: 2013
    ..Using recombinant proteins, we have unambiguously demonstrated the astrovirus VPg can be uridylated by the cognate viral RNA-dependent ..
  19. GM2 Gangliosidosis Therapy Using Neurotropic Enzyme
    Kostantin Dobrenis; Fiscal Year: 2010
    ..b>Recombinant proteins will be screened for enzyme activity and enhanced lysosomal delivery using neuronal cultures from a mouse ..
  20. Targeted delivery of osteoinductive molecules to biologic HA in bone grafts
    Jennifer L Bain; Fiscal Year: 2012
    ..comprised of a highly negative heptaglutamate sequence (E7) that can be added to synthetic peptides and recombinant proteins to achieve an increased concentration, as well as greater retention, of these agents on HA surfaces, thus ..
  21. Validating metabolic pathways in the intracellular pathogen Chlamydia trachomatis
    DEREK JAMES FISHER; Fiscal Year: 2010
    ..including complementation studies in Escherichia coli null mutants, enzyme assays using purified recombinant proteins, and inhibitor assays;2) detecting chorismate from C...
  22. Molecular Genetic Tools for Parasitic Helminths
    Edward J Pearce; Fiscal Year: 2013
    ..sequences that allow conditional transgene expression and both intra- and extracellular transport of recombinant proteins. We will also develop methods for establishing stably expressing transgenic lines through serial host ..
  23. Geographically robust rapid assay for T. cruzi infection
    SYAMAL X RAYCHAUDHURI; Fiscal Year: 2010
    ..In this application, we have described a number of multi-antigenic fusion recombinant proteins including proprietary ITC6 and ITC8.2. The ITC8...
    Sanford J Shattil; Fiscal Year: 2012
    ..These projects will be supported by core units that provide recombinant proteins, cell imaging capabilities and administrative coordination...
  25. Monolithic Media and Technology for Bioprocessing
    ALEX G BONNER; Fiscal Year: 2011
    ..The objective of this work is to develop new manufacturing technology for large-scale production of recombinant proteins. Purification technology for large biomolecules such as monoclonal antibodies is an important component of ..
  26. A protein array platform for anti-citrulline antibodies in Rheumatoid Arthritis
    Ji Qiu; Fiscal Year: 2013
    ..platform to circumvent challenges associated with commercial protein arrays for spotting purified recombinant proteins. NAPPA involves printing full length cDNAs corresponding to proteins of interest on the microarray ..
  27. An immunoadhesin for treatment of hypercholesterolemia
    KEITH WYCOFF; Fiscal Year: 2012
    ..Using a plant expression system we will produce a series of recombinant proteins comprised of EGF- AB variants fused to the Fc of human IgG1...
  28. New Strategies to Prevent Death from Influenza
    Kendall A Smith; Fiscal Year: 2010 blocking the cells that are responsible for producing TNF and other proinflammatory cytokines via recombinant proteins that block the costimulatory T cell molecule OX40, and by activating an inhibitory molecule, CD200R, on ..
  29. Metabolic Engineering of Chinese Hamster Ovary Cells for Production of Heparin
    Susan T Sharfstein; Fiscal Year: 2011
    ..Despite the widespread use of CHO cells for production of recombinant proteins, there are no reports of CHO cells used to produce therapeutic carbohydrates...
  30. Factor XI in Thrombosis
    David Gailani; Fiscal Year: 2013
    ..Studies in Aim 2 will investigate the interaction of fXI with fXIIa using chimeric and mutant recombinant proteins, conventional clotting assays, and whole blood flow models...
  31. DNA-Binding Protein Discovery by the Combinatorial Method REPSA
    Michael van Dyke; Fiscal Year: 2013
    ..3) Validate protein-DNA binding and determine binding specificity using recombinant proteins, point-mutated oligonucleotides, and fluorescence polarization binding assays...
  32. Function of NALT in nasal immunization to heterotypic strains of influenza
    Troy D Randall; Fiscal Year: 2010
    ..We will also test how antigens from CAV or recombinant proteins are delivered to lymphocytes in NALT, whether M cells are a part of this process and whether M cells in ..
  33. Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies
    JEFFREY VICTOR RAVETCH; Fiscal Year: 2013 vitro HIV neutralization and plate-binding assays, a protein expression core to express and purify recombinant proteins required for functional and structural studies, and an animal services core to generate/maintain mice ..
  34. gC1q-R/P33: Structure-function and role in inflammation
    Berhane Ghebrehiwet; Fiscal Year: 2012
    ..Furthermore, the availability of a vast array of recombinant proteins, peptides, and antibodies will also enable us to develop sensitive screening and/or diagnostic assays to ..
    Glenn Wilson; Fiscal Year: 2012
    ..The second aim will evaluate the effects of the recombinant proteins developed in the first aim on the pathogenesis of diabetes in two animal models of type 1 diabetes...
  36. Pathogenic Mechanism for Lung Infection in Mucoid Pseudomonas
    DENNIS EDWARD OHMAN; Fiscal Year: 2013
    ..aeruginosa infections. The results of these studies will also contribute to our overall understanding of bacterial capsule biosynthesis, which is a common mechanism of bacterial virulence for avoiding the host immune response. ..
  37. Modeling monocyte and macrophage based gene therapy for neuroAIDS
    Yuanan Lu; Fiscal Year: 2013
    ..can effectively block the neurotoxic effects of conditioned medium from HIV-1 infected cells or respective recombinant proteins. In this project, we will establish a gene transfer method for high efficiency (>50%), stable ..
    Dan S Ray; Fiscal Year: 2013
    ..The availability of a mitochondrial DNA primase will form the basis of an in vitro system using recombinant proteins and plasmid templates containing minicircle or maxicircle replication origins...
  39. A Heterologous Expression System for Apicomplexa Genes
    JOSE A FERNANDEZ ROBLEDO; Fiscal Year: 2010
    ..parasites available, it becomes evident the need for heterologous expression systems that can generate recombinant proteins, a step required for characterization of protein function, structural studies, production of antigen, ..
  40. High-Grade Astrocytoma-specific Molecular Targeting
    Waldemar Debinski; Fiscal Year: 2013
    ..In this aim, recombinant proteins will be developed for delivering Auger electron emitters directly to GBM cells nuclei...
  41. Regulation of adipose inflammation and metabolic syndrome by adipsin/factor D
    James C Lo; Fiscal Year: 2013
    ..The investigator will employ adipsin-deficient mice for in vivo metabolic studies, recombinant proteins within the adipsin pathway to dissect the mechanism, and test novel adipsin-directed therapies for ..
  42. Regulation of store-operated Ca2+ entry: STIM and ORAI
    Anjana Rao; Fiscal Year: 2013
    ..of the STIM1-ORAI1 interaction;(ii) reconstitute the interaction functionally in minimal systems using recombinant proteins;(iii) identify functional components of larger protein complexes at the plasma membrane of mammalian cells;..
  43. Biotechnology Training in Biomedical Sciences and Engineering
    Yi Tang; Fiscal Year: 2013
    ..genomics, proteomics, protein molecular evolution, and incorporation of unnatural amino acids in recombinant proteins. Such an array of research activities conducted by collaborating researchers provides an exciting menu of ..
  44. TB Vaccine Candidates Found in Patients'Bodily Fluids and Murine MHC-1 Molecule
    Antonio Campos-Neto; Fiscal Year: 2012
    ..The genes coding for most of these antigens have been cloned and the recombinant proteins have been produced and purified...
    Marc A Shuman; Fiscal Year: 2013 to new chemical approaches to characterizing cell surface glyosylated membrane proteins and lipids, recombinant proteins for oxygen delivery, and stem cells for the study of normal and abnormal hematopoiesis...
  46. Protein Biomarkers for Invasive Aspergillosis Diagnostics
    MARTA L FELDMESSER; Fiscal Year: 2013
    ..b>Recombinant proteins then will be used to create monoclonal antibodies that can be used for mass spectrometry-based assay ..
  47. Molecular Genetic Study of von Willebrand Factor
    David Ginsburg; Fiscal Year: 2013
    ..strategy will be used to finely map functional domains within the VWF protein and to select for novel recombinant proteins with potential therapeutic utility...
  48. A Recombinant Protein Vaccine Against Coccidioidomycosis
    GARRY THOMAS COLE; Fiscal Year: 2012
    ..In Specific Aim 2, we will compare the protective efficacy of non-glycosylated recombinant proteins selected on the basis of Specific Aim 1 to genetically-engineered N- glycosylated, O-glycosylated, and both ..
  49. The Role of Acid-active Hyaluronidases in Sperm Function
    ..HYAL2 and 3, acidic hyases, are also expected to play a critical role in IVF and the recombinant proteins can now be used to advance assisted reproductive technology via their addition to the sperm surface, to ..
  50. Characterizing interactions of the VDR and the canonical Wnt signatling pathway
    Hilary F Luderer; Fiscal Year: 2010
    ..In addition, purified recombinant proteins will be generated to determine whether the interaction between the VDR and Lef1 is direct or if additional ..
  51. In vivo proof of efficacy studies for a novel glucosylceramide synthase inhibitor
    JAMES ALAN SHAYMAN; Fiscal Year: 2013
    ..approach for treating these disorders has been through the use of mannose or mannose-6-phosphate terminated recombinant proteins as the basis for enzyme replacement therapy...
  52. Studies of Eicosanoid Biosynthetic Proteins
    Wonhwa Cho; Fiscal Year: 2013
    ..This timely and critical information will accelerate development and evaluation of new therapeutic agents for inflammatory diseases, cardiovascular diseases, and cancer. ..
  53. Coadministration of capsid modified adenovirus for malaria vaccine development
    Alberto Moreno; Fiscal Year: 2013
    ..This proposal wil build on our experience developing chimeric recombinant proteins and recombinant adenovirus vectors to develop a coadministration vaccination regimen that combines these ..
    L David Sibley; Fiscal Year: 2013
    ..Expression of recombinant proteins will be used to develop in vitro activity assays and to screen focused kinase inhibitor libraries to ..
  55. Mechanisms Promoting Angiogenesis in Glioblastoma
    Candece L Gladson; Fiscal Year: 2013
    ..will be tested using GSCs and ECs isolated from GBM of the mesenchymal and pro-neural subtypes using recombinant proteins, antibodies and downregulation approaches to: (1) Determine whether GSC-secreted factors (including VEGF) ..
  56. Novel Influenza A Nanovaccines for Broad Cross Protection
    Baozhong Wang; Fiscal Year: 2013
    ..expressing conformation-stabilized HA stalk domain (csHA-stalk) and tetrameric M2e tandem repeat (tM2et) recombinant proteins. The relatively conserved stalk domain in HA is shielded by its globular head domain in virions and is less ..
  57. Rapid Detection of Antibodies to Adenovirus 36
    Cynthia Chappell; Fiscal Year: 2013
    ..will develop an improved assay by identifying specific epitopes on the AdV36 hexon protein and using recombinant proteins and/or peptides in a simple ELISA-based system to detect evidence of AdV36 infection, i.e...
  58. Recombinant Subunit Vaccine for Tick-Borne Encephalitis
    David E Clements; Fiscal Year: 2011
    ..The recombinant proteins showed very potent immunogenicity in mice when used with modern adjuvants...
  59. Molecular Mechanisms Regulating Early Stage Tick Feeding
    Albert Mulenga; Fiscal Year: 2012
    ..Previous efforts to confer protective tick immunity by immunizing animals with single tick saliva recombinant proteins have produced mixed results...
  60. Development of a Cell-Based HTS for Inhibitors of Inflammatory Macrophages
    David G Russell; Fiscal Year: 2013
    ..This will be achieved either with recombinant proteins or through the quantification of the active proteins in the granuloma-conditioned medium. Aim 2...
  61. Development of a Peptidomic Rapid Point-of-Care TB Diagnostic
    RAYMOND SAM NIEDBALA; Fiscal Year: 2013
    ..tb), and is the only serologic assay under development that is based on peptides rather than recombinant proteins, a feature that assures lower cost and greater specificity and reproducibility...
  62. Novel Pattern Specific Isotopic Labeling of Aromatic Amino Acids
    Robert McFeeters; Fiscal Year: 2010
    ..Thirdly, the incorporation of pattern specific aromatic labels into a range of recombinant proteins will be characterized...
  63. Biochemical analysis of the ER fusion protein allastin
    James A McNew; Fiscal Year: 2013
    ..We will test important predictions of this model using recombinant proteins, in vitro fusion reactions, measurement of GTPase activity, and determination of oligomeric state...
  64. A novel transgenic silkworm system for recombinant glycoprotein production
    Donald L Jarvis; Fiscal Year: 2010
    ..protein production and secretion organ, can be genetically engineered to efficiently produce and secrete recombinant proteins. But, transgenic silkworms have been neither developed nor used for recombinant glycoprotein production...
  65. Development of an Algae-based Membrane Protein Expression System
    ALEXANDER ARAVANIS; Fiscal Year: 2009
    ..These chimeric recombinant proteins accumulate to relatively high levels in thylakoids, demonstrating that these membranes are capable of ..
  66. A SARS-CoV Spike Protein Vaccine
    B Sim; Fiscal Year: 2005
    ..indicates that altering codon usage based on our proprietary information leads to enhanced expression of recombinant proteins and in vivo expression of proteins by DNA vaccines...
    Mark Kay; Fiscal Year: 2005
    ..Work with recombinant proteins has established that hemophilia, caused by mutations in genes encoding Factors VIII or IX in the intrinsic ..
  68. The Treatment of Methotrexate Resistant Rheumatoid Arthritis With Aminopterin
    Stuart Kahn; Fiscal Year: 2009
    ..Alternative treatments include oral drugs that are more toxic, injectable MTX, or injectable recombinant proteins (biologics) that are very expensive...
  69. Recombinant antigen assays for Lassa and other arenaviru
    Robert Garry; Fiscal Year: 2005
    ..GP1 and GP2, and the nucleoprotein (NP) will be expressed in bacteria or eukaryotic cell lines, and the recombinant proteins will be used to immunize mice and rhesus macaques...
  70. Vaccination Against Ixodes scapularis Tick Bites
    Michel Ledizet; Fiscal Year: 2003
    ..Phase I experiments evaluated Salp13 and Salp25D, two recombinant proteins expressed from I. scapularis salivary gland cDNAs, as candidate vaccines...
    Sherrill Slichter; Fiscal Year: 2009
    ..of T-cell epitopes in FVIII may lead to non-immunogenic FVIII replacement therapy while new peptides or recombinant proteins may be useful in tolerance induction for patients with existing antibodies...
    T Harden; Fiscal Year: 2002
    ..and the specificity of their activation by G(alpha(11) and G(alpha)(g) will be determined with native and recombinant proteins. The possibility that one or more of the PLC isoenzymes is activated by pertussis toxin- sensitive G-..
  73. Novel Simulated Moving Bed Chromatography Device to Purify Recombinant Proteins
    ROBERT MIERENDORF; Fiscal Year: 2007
    ..Initiative has been successful in developing high-throughput methods for structural determination of recombinant proteins, focusing on the so-called "low-hanging fruit", i.e...
  74. Bioactive Peptide Coatings for Synthetic Bone Grafts in Dental Applications
    HANNE GRON; Fiscal Year: 2007
    ..will significantly improve their ability to retain exogenously delivered osteogenic factors such as recombinant proteins and progenitor cells...
  75. Peptide-Based Serological Test for Cysticercosis
    VICTOR KOVALENKO; Fiscal Year: 2007
    ..The tests will utilize standardized antigenic material such as synthetic peptides, recombinant proteins and combinations thereof selected from antigens identified recently in diagnostic bands of Western blots (..
    GLEN KWON; Fiscal Year: 2002
    ..such as lipoproteins and viruses are promising targetable transport systems for low molecular weight drugs, recombinant proteins, and genes...
  77. A new technology for preclinical development of functional bispecific antibodies
    Lee A Henderson; Fiscal Year: 2010
    ..trials, the road to a healthier future will require new methods for producing safer and less expensive recombinant proteins. In particular, next generation therapeutics derived from monoclonal antibodies (e.g...
    Bellur Prabhakar; Fiscal Year: 2003
    ..Subsequent to cloning of human TSHR, several laboratories, including our own, have used human recombinant proteins to induce the disease in mice...